Gilead Sciences, Inc.

Hang Chu

Lan Jiang

Hong Yang

Anna E Hurtley

Michael L Mitchell

Jiayao Li

Qiaoyin Wu

David W Lin

Devan Naduthambi

Jennifer R Zhang

Ana Zurisadai Gonzalez Buenrostro

Xiaochun Han

William John Watkins

Darryl Kato

Hongyan Guo

Chandrasekar Venkataramani

Juan A Guerrero

Tetsuya Kobayashi

Jonathan William Medley

Vickie H Tsui

Gregg M Schwarzwalder

Devleena M Shivakumar

Matthew J Von Bargen

Hyung-Jung Pyun

Scott E Lazerwith

Scott D Schroeder

Xiaofen Li

Neil H Squires

John Edward Knox, Jr

Zachary Newby

Tae H Hwang

Nathan D Shapiro

Suzanne M Szewczyk

Qingming Zhu

Gregg M Schwarzwälder

John O Link

Michael Graupe

Gediminas J Brizgys

Chienhung Chou

Julie Farand

James B C Mack

Tezcan Guney

Dong Min Mun

Adam D Zajdlik

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof. Methods associated with the preparation and use of the disclosed compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and uses thereof

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Therapeutic compounds for HIV virus infection

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, L, W, W, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.

MCL1 inhibitors

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Substituted pyridotriazine compounds and uses thereof

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

MCL-1 inhibitors

The present disclosure relates generally to compounds, of Formula I Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer. 

Growing community of inventors

San Mateo, CA, United States of America

Hang Chu